• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Shanghai Novamab Biopharmaceuticals Co., Ltd.

Monday, June 03, 2024
CP
Immunology
Novamab leverages an unparalleled single-domain antibody (sdAb) and unmet clinical needs oriented strategy to establish multiple innovative platforms while incubating competitively positioned first-in-class drugs since founded in 2017. With a robust R&D foundation over 6 years, Novamab has upgraded multiple platforms, including inhaled sdAb, synthetic cytokine surrogate, etc. These advancements encompass more than 10 drug candidates across various therapeutic areas, respiratory diseases, autoimmune diseases, ophthalmology, and oncology. Our flagship drug candidate, LQ036, the FIC inhaled sdAb neutralizing IL-4Rα for asthma and COPD treatment, is currently progressing phase 2 clinical development. Another promising candidate, LQ043H, the first inhaled sdAb neutralizing TSLP for asthma and COPD treatment, is slated to advance into phase 2 trials in 2024. Novamab is actively developing innovative drugs, while simultaneously seeking collaboration and commercial partnerships.
Shanghai Novamab Biopharmaceuticals Co., Ltd.
Company Website: http://en.novamab.com/
Lead Product in Development: Inhaled sdAb platform: LQ036: Inhalable sdAb neutralizing IL-4Rα signaling for asthma and COPD, Phase II LQ043H: Inhalable sdAb neutralizing TSLP signaling for asthma and COPD, Phase Ib/IIa LQ059: Inhalable sdAb targeting Notch2 signaling for cystic fibrosis, Drug Discovery-PCC Synthetic cytokine surrogate sdAb platform: LQ060: sdAb-based biological agonist of IL-10Ra/Rb for autoimmune diseases, Drug Discovery-PCC LQ058: sdAb-based biological agonist of IL-18R1/R2 for multiple cancers, Drug Discovery-PCC Blood-Brain Barrier (BBB) penetrating TfR sdAb delivery platform: LQ061: sdAb-based TfR1 and VEGF bispecific antibody for Glioblastoma, Drug Discovery-PCC Long-acting sdAb platform: LQ080: sdAb-based TL1A/IL-23 p19 bispecific antibody for inflammatory bowel diseases and Scleroderma-associated interstitial lung disease, Drug Discovery-PCC LQ041: sdAb-based IL-5 antibody for eosinophil related inflammation, Drug Discovery-PCC Others: LQ015: VEGF neutralizing sdAb eyedrops for wAMD, Drug Discovery-PCC
Number Of Unlicensed Products (For Which You Are Seeking Partners): 5

Website

http://en.novamab.com/

Company HQ City

Shanghai

Company HQ State

Shanghai

Company HQ Country

China

CEO/Top Company Official

Yakun Wan

Lead Product in Development

Inhaled sdAb platform: LQ036: Inhalable sdAb neutralizing IL-4Rα signaling for asthma and COPD, Phase II LQ043H: Inhalable sdAb neutralizing TSLP signaling for asthma and COPD, Phase Ib/IIa LQ059: Inhalable sdAb targeting Notch2 signaling for cystic fibrosis, Drug Discovery-PCC Synthetic cytokine surrogate sdAb platform: LQ060: sdAb-based biological agonist of IL-10Ra/Rb for autoimmune diseases, Drug Discovery-PCC LQ058: sdAb-based biological agonist of IL-18R1/R2 for multiple cancers, Drug Discovery-PCC Blood-Brain Barrier (BBB) penetrating TfR sdAb delivery platform: LQ061: sdAb-based TfR1 and VEGF bispecific antibody for Glioblastoma, Drug Discovery-PCC Long-acting sdAb platform: LQ080: sdAb-based TL1A/IL-23 p19 bispecific antibody for inflammatory bowel diseases and Scleroderma-associated interstitial lung disease, Drug Discovery-PCC LQ041: sdAb-based IL-5 antibody for eosinophil related inflammation, Drug Discovery-PCC Others: LQ015: VEGF neutralizing sdAb eyedrops for wAMD, Drug Discovery-PCC

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS